1.Evans, D, Ganguli, M, Harris, T, Kawas, C, Larson, EB. Women and Alzheimer disease. Alzheimer Dis Assoc Disord 1999; 13: 187–9.
2.Lopez, OL, Jagust, WJ, DeKosky, ST, et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study: Part 1. Arch Neurol 2003; 60: 1385–9.
3.McCrone, P, Dhanasiri, S, Patel, A, Knapp, M, Lawton-Smith, S. Paying the Price. The Cost of Mental Health Care in England to 2026. London: Kings Fund; 2008.
4.Zandi, PP, Carlson, MC, Plassman, BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: The Cache County Study. JAMA 2002; 288: 2123–9.
5.Comas-Herrera, A, Wittenberg, R, Pickard, L, Knapp, M. Cognitive impairment in older people: future demand for long-term care services and the associated costs. Int J Geriatr Psychiatry 2007; 22: 1037–45.
6.Rocca, WA, Bower, JH, Maraganore, DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007; 69: 1074–83.
7.LeBlanc, ES, Janowsky, J, Chan, BKS, Nelson, HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 2001; 285: 1489–99.
8.Maki, PM, Sundermann, E. Hormone therapy and cognitive function. Hum Reprod Update 2009; 15: 667–81.
9.Shumaker, SA, Legault, C, Rapp, SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 2651–62.
10.Schmid, NS, Taylor, KI, Foldi, NS, Berres, M, Monsch, AU. Neuropsychological signs of Alzheimer's disease 8 years prior to diagnosis. J Alzheimer's Dis 2013; 34: 537–46.
11.Harman, SM, Brinton, EA, Cedars, M, et al. KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric 2005; 8: 3–12.
12.Henderson, VW. Alzheimer's disease: review of hormone therapy trials and implications for treatment and prevention after menopause. J Steroid Biochem Mol Biol 2014; 142: 99–106.
13.World Health Organization. World Health Report: Shaping the Future. Geneva: WHO; 2003.
14.Stewart, DE, Boydell, KM. Psychologic distress during menopause: associations across the reproductive life cycle. Int J Psychiatr Med 1993; 23: 157–62.
15.Gregory, RJ, Masand, PS, Yohai, NH. Depression across the reproductive life cycle: correlations between events. Prim Care Companion J Clin Psychiatry 2000; 2: 127–9.
16.Payne, JL, Roy, PS, Murphy-Eberenz, K, et al. Reproductive cycle-associated mood symptoms in women with major depression and bipolar disorder. J Affect Disord 2007; 99: 221–9.
17.Chuong, CJ, Burgos, DM. Medical history in women with premenstrual syndrome. J Psychosom Obstet Gynaecol 1995; 16: 21–7.
18.Morse, CA, Dudley, E, Guthrie, J, Dennerstein, L. Relationships between premenstrual complaints and perimenopausal experiences. J Psychosom Obstet Gynaecol 1998; 19: 182–91.
19.Binfa, L, Castelo-Branco, C, Blumel, JE, et al. Influence of psycho-social factors on climacteric symptoms. Maturitas 2004; 48: 425–31.
20.Freeman, EW, Sammel, MD, Liu, L, et al. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004; 61: 62–70.
21.Aydin, N, Inandi, T, Karabulut, N. Depression and associated factors among women within their first postnatal year in Erzurum province in eastern Turkey. Women Health 2005; 41: 1–12.
22.Bloch, M, Rotenberg, N, Koren, D, Klein, E. Risk factors associated with the development of postpartum mood disorders. J Affect Disord 2005; 88: 9–18.
23.Bloch, M, Rotenberg, N, Koren, D, Klein, E. Risk factors for early postpartum depressive symptoms. Gen Hosp Psychiatry 2006; 28: 3–8.
24.Schmidt, PJ, Nieman, L, Danaceau, MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000; 183: 414–20.
25.Soares, CN, Almeida, OP, Joffe, H, Cohen, LS. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2001; 58: 529–34.
26.Studd, J, Panay, N. Are oestrogens useful for the treatment of depression in women? Best Pract Res Clin Obstet Gynaecol 2009; 23: 63–71.
27.Studd, J. Ten reasons to be happy about hormone replacement therapy: a guide for patients. Menopause Int 2010; 16: 44–6.
28.Studd, J. Why are estrogens rarely used for the treatment of depression in women? Gynecol Endocrinol 2007; 23: 63–4.
29.Studd, J, Panay, N. Hormones and depression in women. Climacteric 2004; 7: 338–46.
30.Studd, JWW. A guide to the treatment of depression in women by estrogens. Climacteric 2011; 14: 637–42.
31.McEwen, B. Estrogen actions throughout the brain. Recent Prog Horm Res 2002; 57: 357–84.
32.Kenealy, BP, Kapoor, A, Guerriero, KA, et al. Neuroestradiol in the hypothalamus contributes to the regulation of gonadotropin releasing hormone release. J Neurosci 2013; 33: 19051–9.
33.Heldring, N, Pike, A, Andersson, S, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007; 87: 905–31.
34.Craig, MC, Cutter, WJ, van Amelsvoort, TAMJ, Rymer, J, Whitehead, M, Murphy, DGM. Effects of estrogen replacement therapy on dopaminergic responsivity in postmenopausal women. Biol Psychiatry 2003; 53: 210S.
35.Craig, MC, Fletcher, PC, Daly, EM, et al. The interactive effect of the cholinergic system and acute ovarian suppression on the brain: an fMRI study. Horm Behav 2009; 55: 41–9.
36.Davies, P, Maloney, AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403.
37.Bowen, DM, Smith, CB, White, P, Davison, AN. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976; 99: 459–96.
38.Shytle, RD, Silver, AA, Lukas, RJ, et al. Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry 2002; 7: 525–35.
39.van Amelsvoort, TAMJ, Abel, KM, Robertson, DMR, et al. Prolactin response to d-fenfluramine in postmenopausal women on and off ERT: comparison with young women. Psychoneuroendocrinology 2001; 26: 494–502.
40.Dunlop, BW, Nemeroff, CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007; 64: 327–37.
41.Backman, L, Nyberg, L. Dopamine and training-related working-memory improvement. Neurosci Biobehav Rev 2013; 37: 2209–19.
42.Ettigi, P, Lal, S, Martin, JB, Friesen, HC. Effects of sex, oral contraceptives, and glucose loading on apomorphine induced growth hormone secretion. J Clin Endocrinol Metab 1975; 40: 1094–8.
43.Wieck, A, Hirst, AD, Kumar, R, Checkley, SA, Campbell, IC. Growth hormone secretion by human females in response to apomorphine challenge is markedly affected by menstrual cycle phase. B J Clin Pharmacol 1989; 27: 700–1.
44.Wieck, A, Kumar, R, Marks, MN, Checkley, SA. Increased sensitivity of dopamine receptors and recurrence of affective psychosis after childbirth. Br Med J (Clin Res Ed) 1991; 303: 613–16.
45.Craig, M, Cutter, W, Wickhham, H, van Amelsvoort, T, Murphy, D. Effect of long-term estrogen therapy on dopaminergic responsivity in postmenopausal women. Psychoneuroendocrinology 2004; 29: 1309–16.
46.Lamar, M, Craig, M, Daly, EM, et al. Acute tryptophan depletion promotes an anterior-to-posterior fMRI activation shift during task switching in older adults. Human Brain Mapp 2014; 35: 712–22.
47.Halbreich, U, Rojansky, N, Palter, S, et al. Estrogen augments serotonergic activity in postmenopausal women. Biol Psychiatry 1995; 37: 434–41.
48.Matthews, KA, Kuller, LH, Wing, RR, Meilahn, EN, Plantinga, P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996; 143: 971–8.
49.Resnick, SM, Maki, PM, Golski, S, Kraut, MA, Zonderman, AB. Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance. Horm Behav 1998; 34: 171–82.
50.Raz, N, Gunning-Dixon, F, Head, D, et al. Aging, sexual dimorphism, and hemispheric asymmetry of the cerebral cortex: replicability of regional differences in volume. Neurobiol Aging 2004; 25: 377–96.
51.Eberling, JL, Wu, C, Tong-Turnbeaugh, R, Jagurst, J. Estrogen-and-tamoxifen-associated effects on brain structure and function. Neuroimage 2004; 21: 364–71.
52.Erickson, KI, Colcombe, SJ, Raz, N, et al. Selective sparing of brain tissue in postmenopausal women receiving hormone replacement therapy. Neurobiol Aging 2005; 26: 1205–13.
53.Robertson, DMW, Craig, MC, Van Amelsvoort, T, et al. Effects of estrogen replacement therapy on age-related differences in grey matter volume. Climacteric 2009; 12: 301–9.
54.Eberling, JL, Wu, C, Mungas, D, Buoncore, M, Jagurst, J. Preliminary evidence that oestrogen protects against age-related hippocampal atrophy. Neurobiol Aging 2003; 24: 725–32.
55.McEwen, BS. Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism 2005; 54 Suppl 1: 20–3.
56.Robertson, D, Craig, MC, van Amelsvoort, T, et al. Effects of estrogen therapy on age-related differences in gray matter concentration. Climacteric 2009; 12: 301–9.
57.Schmidt, R, Fazekas, F, Reinhart, B, et al. Estrogen replacement therapy in older women: a neuropsychological and brain MRI study. J Am Geriatr Soc 1996; 44: 1307–13.
58.Cook, IA, Morgan, ML, Dunkin, JJ, et al. Estrogen replacement therapy is associated with less progression of subclinical structural brain disease in normal elderly women: a pilot study. Int J Geriatr Psychiatry 2002; 17: 610–18.
59.Raz, E, Tighe, H, Sato, Y, et al. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 1996; 93: 5141–5.
60.Jernigan, TL, Archibald, SL, Fennema-Notestine, C, et al. Effects of age on tissues and regions of the cerebrum and cerebellum. Neurobiol Aging 2001; 22: 581–94.
61.Sullivan, EV, Marsh, L, Mathalon, DH, Lim, KO, Pfefferbaum, A. Age-related decline in MRI volumes of temporal lobe gray matter but not hippocampus. Neurobiol Aging 1995; 16: 591–606.
62.Sherwin, BB, Henrya JF. Brain aging modulates the neuroprotective effects of estrogen on selective aspects of cognition in women: a critical review. Frontiers Neuroendocrinol 2008; 29: 88–113.
63.Eberling, JL, Reed, BR, Coleman, JE, Jagust, WJ. Effect of estrogen on cerebral glucose metabolism in postmenopausal women. Neurology 2000; 55: 875–7.
64.Shaywitz, SE, Shaywitz, BA, Pugh, KR, et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA 1999; 281: 1197–202.
65.Berman, KF, Schmidt, PJ, Rubinow, DR, et al. Modulation of cognition-specific cortical activity by gonadal steroids: a positron-emission tomography study in women. Proc Natl Acad Sci USA 1997; 94: 8836–41.
66.Craig, MC, Fletcher, PC, Daly, EM, et al. Gonadotropin hormone releasing hormone agonists alter prefrontal function during verbal encoding in young women. Psychoneuroendocrinology 2007; 32: 1116–27.
67.Craig, MC, Fletcher, PC, Daly, EM, et al. Reversibility of the effects of acute ovarian hormone suppression on verbal memory and prefrontal function in pre-menopausal women. Psychoneuroendocrinology 2008; 33: 1426–31.
68.Craig, MC, Brammer, M, Maki, PM, et al. The interactive effect of acute ovarian suppression and the cholinergic system on visuospatial working memory in young women. Psychoneuroendocrinology 2010; 35: 987–1000.
69.Jenden, DJ. The metabolism of choline. Bull Clin Sci 1990; 55: 99–106.
70.Pfefferbaum, A, Adalsteinsson, E, Speilman, D, Sullivan, EV, Lim, KO. In vivo spectroscopic quantification of the N-acetyl-moiety, creatine, and choline from large volume of brain grey and white matter: the effects of normal aging. Magn Reson Med 1999; 41: 276–84.
71.Robertson, DM, van Amelsvoort, T, Daly, E, et al. Effects of estrogen replacement therapy on human brain aging: an in vivo 1H MRS study. Neurology 2001; 57: 2114–17.
72.Ernst, T, Chang, L, Cooray, D, et al. The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst 2002; 94: 592–7.
73.Chang, L, Ernst, T, Poland, RE, Jenden, DJ. In vivo proton magnetic resonance spectroscopy of the normal aging human brain. Life Sci 1996; 58: 2049–56.
74.Huang, W, Alexander, GE, Chang, L, et al. Brain metabolite concentration and dementia severity in Alzheimer's disease: a 1H MRS study. Neurology 2001; 57: 626–32.
75.Kugaya, A, Epperson, CN, Zoghbi, S, et al. Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry 2003; 160: 1522–4.
76.Moses, EL, Drevets, WC, Smith, G, et al. Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. Biol Psychiatry 2000; 48: 854–60.
77.Compton, J, Travis, MJ, Norbury, R, et al. Long-term estrogen therapy and 5-HT2A receptor binding in postmenopausal women; a single photon emission tomography (SPET) study. Horm Behav 2008; 53: 61–8.
78.Nobury, R, Travis, MJ, Erlandsson, K, et al.Estrogen therapy and brain muscarinic receptor density in healthy females: a SPET study. Horm Behav 2007; 51: 249–57.
79.Smith, YR, Minoshima, S, Kuhl, DE, Zubieta, JK. Effects of long-term hormone therapy on cholinergic synaptic concentrations in healthy postmenopausal women. J Clin Endocrinol Metab 2001; 86: 679–84.
80.Nobury, R, Travis, MJ, Erlandsson, K, et al. In vivo imaging of muscarinic receptors in the aging female brain with (R,R)[123I]-I-QNB and single photon emission tomography. Exp Gerontol 2005; 40: 137–45.